The only known PP2A modifiers that have progressed into clinical trials for cancer treatment are sodium selenate and LB-100, though in the case of sodium selenate it was determined that a combination therapy would be the most optimal use of this therapeutic agent in cancer [75, 121]. Here, PTPA is linked to cancer.